Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C-CAR088 in Relapsed or Refractory Multiple Myeloma
NCT03815383Phase 1Unknown
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Apr 2019
- Primary completion
- Jan 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of trovocabtagene autoleucel in multiple myeloma (MM), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Treatment-Emergent Adverse Events at 30 days. Status: unknown.
02
Drugs
trovocabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03815383.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03815383.